ERBB2 and inflammatory breast carcinoma: The NOAH trial (ISRCTN86043495, http://www.isrctn.com/) was an open-label phase 3 trial in which newly diagnosed HER2+ LABC or IBC patients were treated with neoadjuvant chemotherapy consisting of doxorubicin, paclitaxel, cyclophosphamide, methotrexate, and fluorouracil with or without trastuzumab (Table 1).